● Recruiting

Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

Condition: Brain Metastases · HR+ Metastatic Breast Cancer · Sponsor: H. Lee Moffitt Cancer Center and Research Institute

PhasePhase 1/Phase 2

Planned participants31

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.

This description comes directly from the study's public registry record.

Talk to the study team

Kamran A Ahmed, MD · 813-745-8424 · Kamran.Ahmed@moffitt.org

Always discuss trial participation with your own doctor first.

Locations (2)

Moffitt Cancer Center	Tampa, Florida, United States	Active Not Recruiting
Ohio State University Comprehensive Cancer Center	Columbus, Ohio, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04923542